MRNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Moderna Inc (MRNA) is not a strong buy for a beginner, long-term investor at this time. While the technical indicators show some bullish momentum, the company's financial performance is weak, with declining revenue, net income, and EPS. Additionally, hedge fund and insider selling trends, coupled with no significant positive catalysts in the news or options data, suggest caution. Analysts' ratings and price targets are mixed, with no clear consensus on strong upside potential. For a long-term investor, it may be better to wait for more clarity on the company's growth trajectory and financial recovery.
The technical indicators show some bullish momentum: MACD is positive and expanding, RSI is neutral at 73.273, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 54.342), with a pre-market price of 54.75. However, the stock's short-term trend indicates a 50% chance of a -3.37% decline in the next week.
Analysts have raised price targets recently, with Piper Sandler projecting a target of $69, citing growth in next-generation COVID vaccines and potential FDA approvals.
The broader healthcare sector is expected to perform well, as noted in recent news.
Hedge funds and insiders are aggressively selling, with insider selling up 89,355.59% in the last month.
Financial performance is deteriorating, with revenue, net income, and EPS all declining significantly YoY.
Litigation risks remain, as Moderna may owe up to $1.3B in additional payments related to settlements.
In Q4 2025, Moderna's revenue dropped by 29.81% YoY to $678M, net income fell by 26.25% YoY to -$826M, and EPS declined by 26.99% YoY to -2.11. However, gross margin improved to 54.57%, up 25.51% YoY.
Analyst ratings are mixed, with price targets ranging from $30 to $69. Some analysts see potential growth in new vaccines and oncology developments, while others remain cautious due to litigation risks and unclear growth trajectories.
